key: cord-0990851-ri8stjtf
authors: Ram, Ananth; Padmanabhan, Sandeep; Warrier, Anup R.; Wilson, Arun
title: Cerebral Malaria in A Patient with COVID-19
date: 2021-03-18
journal: Ann Indian Acad Neurol
DOI: 10.4103/aian.aian_860_20
sha: 4095f44748c5f3c310d55cf6726c570c767b9599
doc_id: 990851
cord_uid: ri8stjtf

nan

Sir, A 64-year-old male, a native of Kochi, Kerala, who is a diabetic, was under quarantine after returning from Nigeria. He was asymptomatic on return but two days later, he was noted to have fever with cough. Patient tested positive for COVID-19 RT-PCR (nasopharyngeal swab). He was started on symptomatic therapy. A week later he deteriorated in sensorium, but had no headache, vomiting, seizures, or neck stiffness. His complete blood count revealed thrombocytopenia [12,000/mm 3 ]. Dengue and Leptospira serology sent were negative. He was started on hydroxychloroquine 400 mg solitary dose followed by weekly doses of hydroxychloroquine 200 mg. A CT of the brain done was normal. Lumbar puncture was deferred in view of thrombocytopenia. He was diagnosed to have COVID-19 Encephalitis.

In view of persistent altered sensorium, he was referred to our center for further management. On arrival, he was drowsy, had no focal deficits or neck stiffness. He was admitted in the COVID Intensive Care Unit at our center.

Blood investigations revealed improving trend in thrombocytopenia [110 K/uL]. A repeat nasopharyngeal swab done for COVID-19 (RT-PCR) was positive. Serum Ferritin was elevated [2974 ng/mL]. MRI of the brain and CSF study done were normal.

In view of travel history to Nigeria, patient was tested for Malaria, where Rapid Malarial Antigen was positive. Peripheral Blood Smear was suggestive of anemia and presence of gametocyte and ring forms of Plasmodium falciparum were seen with Malarial Parasite Index of about 1%. Patient was started on intravenous Artesunate 180 mg once daily for 3 days followed by oral arterolane (150 mg) and piperaquine (750 mg) combination for 3 days. Smear for malarial parasite repeated after three days was again positive and a second course of intravenous artesunate was given. SARS-CoV2 RTPCR was negative and so was the peripheral blood smear for malarial parasite.

Patient improved in sensorium gradually and at the time of discharge, he was conscious and oriented with absent malarial parasite and normal blood counts.

Co-infection with COVID-19 is known to be in about 7% of the patients, with doubling the rate in ICU patients. [1] Bacterial infections are known to be most common co-infections.

Altered consciousness in the form of confusion, delirium, deep coma is considered as the hallmark features of COVID encephalitis in a positive COVID patient. [2] The presence of anosmia and aguesia helps in differentiating it from other encephalopathies. Neuroimaging features such as cortical and subcortical T2/FLAIR signal changes are MRI features of COVID encephalopathy.

Our patient had cerebral malaria as per WHO Criteria. [3] Cerebral Malaria has a mortality of up to 50% if left untreated. Our patient mostly survived probably due to hydroxychloroquine intake. Not all patients with encephalopathy when positive for COVID-19 are encephalitis due to COVID-19 infection. Nigeria is a country where malaria is endemic and special importance is to be given to travel history in such a case.

Every suspected case of COVID Encephalitis has to be investigated for all possible causes of encephalitis as co-infection. Not all encephalitis or encephalopathy in COVID-19 patients are due to SARS-CoV2 infection.

Nil.

Clinical characterization of genetically diagnosed cases of spinocerebellar ataxia type 12 from India

Evidence of a common founder for SCA12 in the Indian population

Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with SCA12

Identification of 46 CAG repeats within PPP2R2B as probably the shortest pathogenic allele for SCA12

Mutational screening of 320 Brazilian patients with autosomal dominant spinocerebellar ataxia

Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia

Prevalence and ethnic differences of autosomal-dominant cerebellar ataxia in Singapore

Genetic testing for clinically suspected spinocerebellar ataxias: Report from a tertiary referral centre in India

Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B

Spinocerebellar ataxia type 12 is not an uncommon form of ADCA in India

Co-infections in people with COVID-19: A systematic review and meta-analysis

Encephalitis as a clinical manifestation of COVID-19

Cerebral malaria and bacterial meningitis

Sir, Prostate cancer is the second most common cancer diagnosis made in men. [1] Neurological manifestations described in prostate cancer are usually related to metastasis, local pelvic growth, or treatment-related. However, Chronic inflammatory demyelinating polyneuropathy (CIDP) has rarely been reported with prostatic adenocarcinoma. In this report, we describe a case of acute onset CIDP in a patient with prostatic adenocarcinoma.A 70-year-old gentleman with obstructive urinary symptoms was diagnosed with prostate adenocarcinoma after prostatic biopsy in our hospital. After one month, he experienced progressive weakness of all four limbs over 2 weeks without any perceived sensory loss or bowel bladder symptoms. Neurological examination revealed bilateral mild lower motor neuron (LMN) facial palsy. Power testing (MRC grading) revealed a grade of 3 in all limbs with absent deep tendon reflexes. The vibration test showed early decay in both lower limbs till the knee. However, proprioception, pain, and touch sensations were intact. The rest of the neurological and systemic examination was normal.On the basis of clinical finding of flaccid quadriparesis with areflexia alongwith LMN facial palsy progressing over 2 weeks, the diagnosis of acute onset neuropathy was kept. Myopathy and neuromuscular disorders were ruled out initially due to sensory involvement, areflexia and muscle weakness without diurnal variation.Her initial laboratory workup showed pancytopenia with haemoglobin 12.0 g/dL, white cell count 6 × 10 3 /µL, and platelets 220 × 10 3 /µL. The patient's aspartate aminotransferase was 27, alanine aminotransferase was 25 and alkaline phosphatase was 30. The coagulation profile and kidney function tests (urea of 18 mg/dl and creatinine of 0.9) were